Amicus Therapeutics
#4736
Rank
$1.76B
Marketcap
United States
Country
Mr. John F. Crowley (Exec. Chairman)
Mr. Bradley L. Campbell M.B.A. (CEO, Pres & Director)
Ms. Daphne E. Quimi CPA, M.B.A. (Chief Financial Officer)
Summary
History
Amicus Therapeutics was founded in 2002 to develop innovative therapies for rare, devastating diseases that lack effective treatments. Over the years, the company has invested heavily in research to successfully bring new treatments to market. The company has taken a rare disease focus and has become one of the largest biotech companies in the world.
Mission
Vision
Key Team
Ms. Ellen S. Rosenberg (Chief Legal Officer & Corp. Sec.)
Mr. David M. Clark (Chief People Officer)
Andrew Faughnan (Sr. Director of Investor Relations)
Ms. Samantha Prout (VP, Global Controller & Principal Accounting Officer)
Dr. Jill Weimer Ph.D. (Chief Science Officer)
Mr. Patrik S. Florencio (Sr. VP, Global Chief Compliance & Risk Officer)
Ms. Diana Moore (Head of Global Corp. Communications)
Recognition and Awards
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Mr. John F. Crowley (Exec. Chairman)
Mr. Bradley L. Campbell M.B.A. (CEO, Pres & Director)
Ms. Daphne E. Quimi CPA, M.B.A. (Chief Financial Officer)